Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$0.57 USD
-0.04 (-6.16%)
Updated May 8, 2024 04:00 PM ET
After-Market: $0.58 +0.01 (2.56%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Atara Biotherapeutics, Inc. [ATRA]
Reports for Purchase
Showing records 81 - 100 ( 108 total )
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Notable Events/Catalysts from Our Coverage Universe for the Remainder of 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20: Progressing Pipeline. Immediate Focus tab-cel BLA Filing by 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Financials Reported; Reiterate Buy; Raising PT to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Sclerosis Therapy Shows Improvement in Disability
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
See Our Highlights from AACR II (June 22-24, 2020) Meeting Abstracts
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Continuing Work at Atara To Advance The EBV Platform
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An EBV-Specific Cell Therapy Platform Is Atara''s Mission for 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Like tab-cel Data Ahead of Phase III Readouts
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19: tab-cel Hitting the BLA Timeline is Critical!
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T